Alzheimer-CAG
The Translational Neuroscience Clinical-Academic Group (CAG) for Alzheimer´s disease
The Translational Neuroscience CAG for AD is launching its activities in January 2021, supported by funding provided by the Liaison Committee for Education, Research and Innovation in Central Norway (Samarbeidsorganet HMN-NTNU).
The overarching aim of the Translational Neuroscience CAG for AD is to coordinate and strengthen the collaboration and synergies between ongoing relevant research activities in the region as well as foster new collaborations towards the unifying goal of providing novel insights into the pathogenetic mechanisms, diagnostics and treatment of AD patients and to create regional health services that benefit patients, caregivers and the society. This includes creating increased opportunities to provide personalized care and treatment to AD patients in the future.
Specific objectives of the CAG include stimulating and implementing research that aims to:
- Elucidate key pathogenesis of AD and improve diagnosis using novel biomarkers;
- Determine the effect of comorbidities on diagnosis and treatment;
- Improve diagnosis by applying and validating state-of-the-art and emerging clinical biomarkers.
Additionally, through designated networking, training and communication activities the CAG´s objectives also include:
- Create high-quality collaboration in specialist health care in the region.